Fosun Pharmaceutical subsidiary has obtained the exclusive sales license of neurotoxin rt002

On December 5, Fosun Pharmaceutical announced that its holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd was licensed by revancetherapeutics, Inc to exclusively use, import, sell and other commercial (excluding manufacturing) injection drugs (rt002) containing botulinum toxin A type botulinum toxin developed by revance in the region and in the field Fosun Pharmaceutical Industry shall pay up to US $88 million in license fees and corresponding sales milestone payments to revenue as agreed According to the agreement, Fosun Pharmaceutical industry is authorized to use and import exclusively in the region (i.e mainland China, Hong Kong and Macao Special Administrative Region) and in the field (i.e any use of the following indications: Beauty indications including but not limited to eyebrow wrinkles; treatment indications including but not limited to cervical dystonia, plantar fasciitis, upper extremity spasm and chronic migraine) , sales and other commercialized (excluding manufacturing) injection drug rt002 containing botulinum toxin type A botulinum toxin In addition, Fosun Pharmaceutical industry has the right to sublicense its rights granted under the license agreement to its affiliated parties after notifying revenue; after obtaining the consent of revenue, Fosun Pharmaceutical industry has the right to sublicense its rights granted under the license agreement to a third party The following is the full text of the announcement: